In the 1990s, exendin-4, a GLP-1 receptor agonist (GLP-1 RA) structurally similar to endogenous GLP-1, was isolated from Gila monster venom, which subsequently led to the approval of exenatide for type 2 diabetes mellitus (T2DM) management in 2005 [2]
Regarding lack of access to the Bridge Program, we want to clarify the following: Under federal law, Medicare Part D plans cannot cover medications prescribed for weight loss Medications that are FDA-approved for both weight loss and other indications may only be covered by Part D plans for non-weight loss indications. This Bridge Program is a trial of a way to address the particular problem of Part D restrictions on weight-loss prescriptions
And that came from a recent trial that was published in the New England Journal of Medicine
However, the limited follow-up duration of 6 months raised concerns about potential reverse causality, as undetected suicidal ideation and medical conditions might have influenced the choice of particular anti-obesity or anti-diabetic drugs
How do you start a GLP-1 weight-loss medication